PepGen Withdraws Guidance on Launch of Study for Muscle Disease Treatment
2023年6月14日 - 6:07AM
Dow Jones News
By Sabela Ojea
PepGen said Tuesday that it is withdrawing its prior guidance on
the timeline to initiate a Phase 1 study of Pgn-Edodm1 to treat the
muscle disease myotonic dystrophy type 1.
Shares dropped 9.5% to $12 in after-hours trading. The stock had
gained nearly 11% to close at $13.26 during the regular session,
after closing at a near-two-month low on Monday.
The clinical biotechnology company has paused additional
regulatory filings for clearance to initiate the Phase 1 study to
address the official hold letter it awaits from the Food and Drug
Administration.
"We will continue to work closely with the FDA to lift the
clinical hold whilst we remain fully committed to initiating a
Phase 1 study of Pgn-Edodm1 as quickly as feasible," President and
Chief Executive James McArthur said.
Myotonic dystrophy is a genetic disorder that causes progressive
muscle weakness.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
June 13, 2023 16:52 ET (20:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
PepGen (NASDAQ:PEPG)
過去 株価チャート
から 4 2024 まで 5 2024
PepGen (NASDAQ:PEPG)
過去 株価チャート
から 5 2023 まで 5 2024
